On December 2, 2024, the company reported data showing that the combination of daraxonrasib with pembrolizumab in NSCLC was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback